Troy A. Ignelzi
- CFO at Rapport Therapeutics RAPP: 1 buys, 0 sales
- CFO at Karuna Therapeutics: 0 buys, 8 sales
Full history from EDGAR: holdings now, every transaction and Form 144 planned sales
Every trade, with what the company filed around it
Open-market buys and sales as each Form 4 states them, newest first.
How these figures work
Notes on each row are as each Form 4 states them, next to SEC Tracker's own records of the company's filings and other insiders' buys. Holding after is what the filing reports they held after the trade, with the change in their holding.
| Date | Company | Trade | Value | Holding after | Notes |
|---|---|---|---|---|---|
| Oct 21, 2026 | Rapport Therapeutics RAPP | Bought 5,500 sh at $26.10 Their first open-market buy here in SEC Tracker's records. One of 6 insiders who bought $1.7M over 3 days, within the 30-day window. 1 day after the company's 8-K filed Oct 20, 2026. | $144K | 15,500 +55% | Their first open-market buy here in SEC Tracker's records. One of 6 insiders who bought $1.7M over 3 days, within the 30-day window. 1 day after the company's 8-K filed Oct 20, 2026. |
| Apr 21, 2022 | Karuna Therapeutics | Sold (10b5-1) 40 sh at $134.46 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 163 days after the company's 8-K filed Nov 9, 2021. | $5K | 24,970 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 163 days after the company's 8-K filed Nov 9, 2021. |
| Apr 20, 2022 | Karuna Therapeutics | Sold (10b5-1) 704 sh at $133.20 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 162 days after the company's 8-K filed Nov 9, 2021. | $94K | 24,970 −3% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 162 days after the company's 8-K filed Nov 9, 2021. |
| Apr 19, 2022 | Karuna Therapeutics | Sold (10b5-1) 3,500 sh at $130.81 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 161 days after the company's 8-K filed Nov 9, 2021. | $458K | 24,970 −12% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 161 days after the company's 8-K filed Nov 9, 2021. |
| Nov 8, 2021 | Karuna Therapeutics | Sold (10b5-1) 13,500 sh at $152.32 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 250 days after the company's 8-K filed Mar 3, 2021. | $2.1M | 18,000 −43% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 250 days after the company's 8-K filed Mar 3, 2021. |
| Nov 10, 2020 | Karuna Therapeutics | Sold 118 sh at $103.48 The filing does not mark this sale as under a Rule 10b5-1 plan. 344 days after the company's 8-K filed Dec 2, 2019. | $12K | 5,000 −2% | The filing does not mark this sale as under a Rule 10b5-1 plan. 344 days after the company's 8-K filed Dec 2, 2019. |
| Nov 9, 2020 | Karuna Therapeutics | Sold (10b5-1) 8,000 sh at $105.02 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 343 days after the company's 8-K filed Dec 2, 2019. | $840K | 5,000 −62% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 343 days after the company's 8-K filed Dec 2, 2019. |
| Nov 9, 2020 | Karuna Therapeutics | Sold 1,318 sh at $108.26 The filing does not mark this sale as under a Rule 10b5-1 plan. 343 days after the company's 8-K filed Dec 2, 2019. | $143K | 5,000 −21% | The filing does not mark this sale as under a Rule 10b5-1 plan. 343 days after the company's 8-K filed Dec 2, 2019. |
| Nov 6, 2020 | Karuna Therapeutics | Sold 564 sh at $108.15 The filing does not mark this sale as under a Rule 10b5-1 plan. 340 days after the company's 8-K filed Dec 2, 2019. | $61K | 5,000 −10% | The filing does not mark this sale as under a Rule 10b5-1 plan. 340 days after the company's 8-K filed Dec 2, 2019. |
Open-market trades are Form 4 transaction codes P (purchase) and S (sale). Planned sales are those the filing marks as made under a Rule 10b5-1 plan. A P-code buy at the offering price within a day of the company's FWP, 424B prospectus or offering 8-K is marked Bought in the offering and left out of open-market buy counts and cluster buys. Prices and values are as stated in each Form 4. Stock prices aren't shown on this page. Not investment advice.